BioStem Technologies Inc. Enters Into Consulting and Advisory Agreement with Dr. Irmgard Huber

Pompano Beach, FL, April 04, 2018 -- BioStem Technologies, Inc. (OTC: BSEM) (“BioStem” or the “Company”), a global life sciences corporation, providing innovative technologies with a focus in Pharmaceuticals and Regenerative Medicine, today announced that it has entered into an agreement with Irmgard Huber, M.D. to serve as BSEM’s International Medical Advisor and Interim Chief Medical Officer.

Dr. Irmgard Huber has been a Medical Doctor for 27 years, receiving her Approbation (German Medical License) in 1991. She earned her medical degree from a leading German Medical School and spent three years at Harvard Medical School, first on a DAAD exchange student scholarship, and then as a fellow at Harvard’s Dana-Farber Cancer Institute, where she was engaged in molecular genetic research. Dr. Huber has spent more than two decades on the business side of the healthcare industry, her career being in the pharmaceutical industry. She has developed a reputation as a serial entrepreneur, building highly profitable and very innovative ‘Start-Up’ companies, primarily in ambulatory care, including the first and largest laser refractive laser chain in Germany. With her solid extensive medical and start-up background, she has helped to advise investors on where to place their investments and companies on how to deliver optimal returns to their shareholders.

Commenting on the Company’s new executive, BioStem’s Chief Revenue Officer, Larry Jones said, “We are very pleased to have Dr. Huber join our experienced team. She is very passionate about developing and applying innovative medical strategies and will contribute her outstanding experience to assure continued progress and success in implementing cutting-edge stem cell and regenerative medicine therapies for the well-being of our patients."  

About BioStem Technologies, Inc. (OTC PINK: BSEM): BioStem Technologies, Inc. is a global life sciences corporation, providing innovative technologies with a concentration in Pharmaceuticals and Regenerative Medicine. The Company’s mission is to discover, develop and produce the most effective Pharmaceutical and Regenerative Medicine products in the world. The Company is comprised of a diverse group of scientists, physicians, and entrepreneurs who collaborate to create innovative products. These technologies improve the Quality of Life for our patients and, as a result, drive shareholder value.

Forward-Looking Statements: Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "future," "plan" or "planned," "expects," believe" or "projected." These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing, exploiting and protecting proprietary technologies, intense competition and additional risk factors, as discussed in reports filed by the Company with OTC Markets.

BioStem Technologies, Inc.
Phone: 954-380-8342
Website: http://www.biostemtech.com
Email: [email protected]
Twitter: @Biostemtech
Facebook: BioStem Technologies

Investor Relations:
Andrew Van Vurst
[email protected]
(954) 380-8342